Sagar Lonial Discusses Treating Patients With Myeloma
Sagar Lonial, MD, chief medical officer, Winship Cancer Institute of Emory University and Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treating patients with myeloma.
Sagar Lonial, MD, chief medical officer, Winship Cancer Institute of Emory University and Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treating patients with myeloma.
Lonial says that care should be directed by a myeloma expert who can define a treatment plan over the next 6 to 12 months.
While new treatment options for myeloma have recently emerged, Lonial says it’s important for providers to know when to treat and when not treat with a new drug. He adds that patients should be encouraged to admit any adverse events, particularly neuropathy or fatigue, which can impact quality of life.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
